| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | SURPASS and SURMOUNT Phase III RCT programs across T2D and obesity. FDA approved (Mounjaro, Zepbound). Multiple head-to-head trials vs semaglutide. |
25 / 25 |
| Sample Size | SURMOUNT-1 enrolled 2,539. SURPASS program collectively over 10,000 across trials. |
20 / 20 |
| Replication | Replicated across multiple independent research groups and trial programs. Slight deduction: newer compound with shorter replication timeline vs GLP-1 class overall. |
18 / 20 |
| Journal Impact Factor | SURPASS and SURMOUNT primary papers published in NEJM (IF ~96). A-journal primary data. |
15 / 15 |
| Funding Independence | Eli Lilly funded all major trials. Pre-registered, rigorously conducted, but no independent major funding sources identified. |
3 / 10 |
| Population Diversity | SURPASS program enrolled globally across diverse demographics. SURMOUNT-1 included diverse US population. |
5 / 5 |
| Researcher h-Index | Lead investigators include Juan Frias and Ania Jastreboff — both with h-Indexes above 20 in endocrinology. |
5 / 5 |